Drug Development: A Money Pit?
July 8, 2014
Hosted by Samuel D. Brinkman, Ph.D.
Dr. Jeffrey Cummings, a highly respected Alzheimer’s researcher, recently reported that over 99% of drug trials from 2002-2012 for treatment of Alzheimer’s disease have failed to show benefit. What is the current state of drug development? Is research into drug treatments a bottomless money pit or a necessary investment? Join Dr. Brinkman as he discusses this complex topic on the interface of science and politics.
NeuroMatters: The Brink of Alzheimer’s
Archives Available on VoiceAmerica Health and Wellness Channel
Our program is about Alzheimer’s disease and the many other disorders that can cause dementia. There are over 5 million Americans who currently struggle with Alzheimer’s disease alone, some of whom are in their 40s and 50s. Others struggle with vascular dementia, Lewy body disorder, frontotemporal dementia, Parkinson’s disease, and other conditions. This program brings together nationally recognized experts from many professional fields relevant to the dementias in order to provide current information about these disorders. These nationally recognized experts are from areas of research, diagnosis, clinical care, and management, caregiver education and support, medication treatments and drug development research, non-medication approaches to treatment, public education, and advocacy. We will give people who have been affected by Alzheimer’s disease and other dementias a forum to talk with and learn from these experts.
Samuel D. Brinkman, Ph.D.
Dr. Brinkman is a clinical neuropsychologist who has been involved in Alzheimer's disease research and clinical care for over 30 years. Research activities have included issues of diagnosis and treatment. He graduated from the University of Houston in 1980.
Dr. Brinkman has a private practice at Texas Neuropsychology Clinic, LLC in Abilene, Texas. He is on the adjunct faculty of Hardin-Simmons University Doctor of Physical Therapy Program, where he teaches a course on neuroscience. He is a member of the Board of Directors of the North Central Texas Chapter of the Alzheimer Association. He was recently co-chair of the National Delegate Assembly of the Alzheimer Association.
Dr. Brinkman is also president of Dementia Screening, Inc. He is the developer of the GrayMatters(r) screening system, a computerized, self-administered assessment procedure which provides information regarding an individual’s memory and executive functioning and likelihood of early dementia.
Dr. Brinkman has been involved in other professional activities, such as reviewing manuscripts submitted for publication to refereed journals, participating as a member of a site visit team for the National Institutes of Health, and contributing to the development of the Texas State Alzheimer Care Plan. He has published research on Alzheimer’s disease, vascular dementia, and other neurological conditions.